Breaking barriers to access intracellular targets with T-cell engagers: Discovery of diverse, developable, and ultra-specific antibodies against a MAGE-A4 pMHC

post

Tortora D, et al. American Association for Cancer Research® (AACR) Annual Meeting, April 2023

This poster describes the discovery of highly specific and developable antibodies against a validated peptide-major histocompatibility complex (pMHC) tumor target, MAGE-A4-pMHC. Fully human MAGE-A4-pMHC-binding antibodies were identified using integrated antibody discovery, characterization, and engineering technologies. These data illustrate how strategic selection and pairing of AbCellera’s target- and CD3-binding antibodies has the potential to generate optimal T-cell engagers against challenging pMHC targets.

DOI: 10.1158/1538-7445.AM2023-1891

AbCellera AACR 2023 Poster - pMHC
Download poster

Further reading:

  1. Tortora D, et al. Cancer Res (2024) 84 (6_Supplement): 2373.
  2. Tortora D, et al. J Immunother Cancer 2023;11(Suppl 1):A1–A1731.